Michael Goettler, Viatris CEO

First in­ter­change­able biosim­i­lar launch­es in the US with a tiny dis­count on list price

Vi­a­tris (for­mer­ly known as My­lan and Pfiz­er’s Up­john) on Tues­day opened up on the pric­ing of its in­ter­change­able biosim­i­lar for the in­sulin Lan­tus, say­ing the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.